Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Search Seller Projects – , Healthcare

Page of 5
Asia: Japan

Japanese new human absorbable painless micro needle company seeks C-round financing of USD 7.46 million - 11.18 million.

The Japanese company is mainly engaged in R&D and production of medical products with optical and electrical technologies. The main products are painless needles with laser processing technology, which can be used in skincare and beauty, medical anesthesia, preventive needles, and other fields. The company completed Round B+ financing at the end of 2020, with overall B-round financing of USD 5.29 million (JPY 710 million). It seeks Round C financing of USD 7.46 million - 11.18 million (JPY 1 billion - 1.5 billion) and plans to complete the IPO by the end of 2023.
Asia: Japan

Japanese non-intrusive blood glucose testing company seeks financing.

The Japanese company focuses on the development of intelligent wearable devices. Its non-intrusive blood glucose monitoring technology can avoid the harm to the body caused by the traditional blood glucose detection method while achieving the same detection effect as the traditional detection method. The core team members come from famous companies such as Sony, Toshiba, Dentsu and Toyota Tsusho Systems, and have rich experience in enterprise management and software and hardware development of electronic products. Since its establishment, the company has received USD 10 million from Taisho Pharmaceutical Group, Tomita and Alfresa Holdings. Now the company seeks financing.
Asia: Japan

Japanese microbial gene data innovation platform seeks financing.

The Japanese company has exclusively developed single-cell genome analysis technology, which is the only effective technology that can obtain the complete genome sequence of microorganisms at present and can be used to serve the leading compound discovery, compound structure optimization, target gene research and other fields involved in the clinical development of pharmaceutical enterprises. The company has 19 employees. The four core founding team members come from well-known universities such as the University of Tokyo, Tokyo University of Agriculture and Technology and Kobe University, and have work experience in international pharmaceutical companies, scientific research institutions, the Boston Consulting Group and other institutions. In 2020, the company obtained B-round financing of USD 5.43 million (JPY 730 million), seeking C-round financing to expand to the Chinese market through technology licencing.
Asia: Japan

Japanese general hospital seeks 100% acquisition of USD 133.9 million or other proportions.

The Yokohama general hospital is a large general hospital with 300 beds. It has internal medicine, psychiartry, pediatric orthopaedics, sports orthopaedics, breast surgery, rheumatology, plastic surgery, gynecology and obstetrics, urology, ophthalmology, otorhinolaryngology, dermatology, dentistry, oral surgery and anethesiology. The hospital is 36 minutes' drive from Haneda Airport. Its opening date is December 1976. Its land for facilities is 20,485 square meters. There are 155 parking spaces in the parking lot and 24 parking spaces for the disabled. The hospital seeks 100% acquisition of USD 133.9 million (JPY 18 billion) or other proportions can be consulted (sales volume is not disclosed).
Asia: Japan

Japanese hospital seeks Chinese partners and to sell 60% or more equity.

The Japanese hospital has the following diagnosis and treatment departments: neurosurgery, nephrology, hematology, respiratory, gastroenterology, cardiovascular, endocrinology, pediatrics, surgery, orthopaedics, psychiatry, neurology, dental and oral surgery, rehabilitation, anesthesiology, otorhinolaryngology, urology, ophthalmology and gynecology. The hospital has 296 beds and can undertake medical travel projects. It seeks Chinese partners and to sell 60% or more equity.
Asia: Hong Kong SAR

Hong Kong owned Foshan medical clinic seeks new owner or cooperation.

The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics, pediatrics, pediatric surgery, children's health care, ophthalmology, otorhinolaryngology, stomatology, dermatology, traditional Chinese medicine inspection, imaging (ultrasound, electrocardiogram ("ECG")). The expiry date of the clinic lease is July 31, 2028. The medical licence is valid until 2026. The company has professional qualifications in ophthalmology, stomatology and dermatology and decoration equipment. It has 24 consulting rooms and 2 dental chairs. It is brand new high-end decorated, which has not yet been opened for use, and is ready for opening at any time. The company is Hong Kong-listed. It seeks the sale of the outpatient department clinic in Foshan or cooperation.
Asia: Hong Kong SAR

Hong Kong owned Foshan medical clinic seeks new owner or cooperation.

The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics, pediatrics, child health care, ophthalmology, otorhinolaryngology, stomatology, traditional Chinese medicine inspection, and imaging (ultrasound, electrocardiogram ("ECG")). The expiry date of the clinic lease is July 31, 2029. The medical licence is valid till 2025. The company is surrounded by high-end residential and commercial areas. It has ophthalmology and stomatology qualifications and decoration settings. Besides, it has 9 consulting rooms, complete treatment room, laboratory and ultrasound room. It is Hong Kong-listed. The company seeks the sale of the clinic in Foshan or cooperation.
Asia: Hong Kong SAR

Hong Kong owned Suzhou pediatric clinic seeks new owner or cooperation.

The Hong Kong company engages in pediatrics and laboratory. It has 2 complete consulting rooms and 1 laboratory. The expiry date of the clinic lease is July 15, 2023. The company is Hong Kong-listed. It seeks the sale of the clinic in Suzhou or cooperation.
Asia: Hong Kong SAR

Hong Kong owned Chengdu children health center seeks new owner or cooperation.

The Hong Kong company engages in children's health care, which does not require the application for medical practice licence. The expiry date of the clinic lease is December 31, 2030. The company is Hong Kong-listed. It seeks the sale of the clinic in Chengdu or cooperation.
Asia: Hong Kong SAR

Hong Kong owned Chengdu clinic seeks new owner or cooperation.

The Hong Kong company's scope of medical qualifications include internal medicine, pediatrics, gynecology, surgery, women's health care, children's health care, ophthalmology, otorhinolaryngology, stomatology, dermatology, traditional Chinese medicine inspection, and imaging (ultrasound). The company has a comprehensive medical licence and the speciality qualification and decoration setting of dermatology, stomatology and women's and children's health care. It is Hong Kong-listed. Its medical licence is valid from May 26, 2020 to May 25, 2025. The company seeks the sale of the clinic in Chengdu or cooperation.
Asia: Hong Kong SAR

Hong Kong owned Beijing clinic seeks new owner or cooperation.

The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics (gynecology), pediatrics, ophthalmology, otorhinolaryngology, stomatology, dermatology, psychiatry, traditional Chinese medicine inspection, and imaging (X-ray, ultrasound, electrocardiogram ("ECG")). In the Chaoyang district of Beijing, the comprehensive outpatient department licence is scarce. The company is Hong Kong-listed. It seeks the sale of the clinic in Beijing or cooperation.
Asia: Japan

Japanese health products company seeks to sell 90% equity

The Japanese company is mainly engaged in the original equipment manufacturer ("OEM") production of health food, medicines, quasi medicines, cosmetics and other products, among which health food accounts for 75%. The company has 700 employees. In 2019, the company's revenue is USD 165.36 million (JPY 21.2 billion), earnings before interest ("EBITDA") is USD 2.5 million (JPY 320 million), and net profit is USD 8.58 million (JPY 110 million). The company seeks to sell 90% equity.

Filter

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive